| Literature DB >> 34975797 |
Arundhati Mehta1, Yashwant Kumar Ratre1, Krishna Sharma2, Vivek Kumar Soni1, Atul Kumar Tiwari3, Rajat Pratap Singh1, Mrigendra Kumar Dwivedi4, Vikas Chandra1, Santosh Kumar Prajapati5, Dhananjay Shukla1, Naveen Kumar Vishvakarma1.
Abstract
The consequences of COVID-19 are not limited to physical health deterioration; the impact on neuropsychological well-being is also substantially reported. The inter-regulation of physical health and psychological well-being through the psychoneuroendocrineimmune (PNEI) axis has enduring consequences in susceptibility, treatment outcome as well as recuperation. The pandemic effects are upsetting the lifestyle, social interaction, and financial security; and also pose a threat through perceived fear. These consequences of COVID-19 also influence the PNEI system and wreck the prognosis. The nutritional status of individuals is also reported to have a determinative role in COVID-19 severity and convalescence. In addition to energetic demand, diet also provides precursor substances [amino acids (AAs), vitamins, etc.] for regulators of the PNEI axis such as neurotransmitters (NTs) and immunomodulators. Moreover, exaggerated immune response and recovery phase of COVID-19 demand additional nutrient intake; widening the gap of pre-existing undernourishment. Mushrooms, fresh fruits and vegetables, herbs and spices, and legumes are few of such readily available food ingredients which are rich in protein and also have medicinal benefits. BRICS nations have their influences on global development and are highly impacted by a large number of confirmed COVID-19 cases and deaths. The adequacy and access to healthcare are also low in BRICS nations as compared to the rest of the world. Attempt to combat the COVID-19 pandemic are praiseworthy in BRICS nations. However, large population sizes, high prevalence of undernourishment (PoU), and high incidence of mental health ailments in BRICS nations provide a suitable landscape for jeopardy of COVID-19. Therefore, appraising the interplay of nutrition and PNEI modulation especially in BRICS countries will provide better understanding; and will aid in combat COVID-19. It can be suggested that the monitoring will assist in designing adjunctive interventions through medical nutrition therapy and psychopsychiatric management.Entities:
Keywords: BRICS; COVID-19; immunity; neuropsychology; nutrition
Year: 2021 PMID: 34975797 PMCID: PMC8718880 DOI: 10.3389/fmicb.2021.769884
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1BRICS nations share in confirmed cases worldwide.
Figure 2The number of deaths due to COVID-19 in BRICS nations and the rest of the world.
Figure 3Prevalence of undernourishment (PoU) in BRICS nations.
Figure 4Prevalence of individuals with depression among the population of BRICS nations.
COVID-19 vaccine being used in BRICS nations.
| Country | Vaccines | Vaccine type | Route | Developer | Manufacturer/Importer | Approval |
|---|---|---|---|---|---|---|
| Brazil | Sputnik V | Adenovirus viral vector, RNA | IM | Gamaleya Research Institute of Epidemiology and Microbiology | Restricted use | |
| BNT162b1 | RNA | IM | Pfizer Inc., BioNTech | Under trial (III) | ||
| BNT162b2 | RNA | IM | Pfizer Inc., BioNTech | Approved | ||
| Ad26.COV2.S | Non-replicating viral vector | IM | Johnson & Johnson (Janssen) | Approved | ||
| Covishield | Non-replicating viral vector | IM | Oxford University, Astrazeneca, Serum Institute of India | Approved | ||
| Oxford/Astrazeneca formulation | Non-replicating viral vector | IM | Oxford University + Astrazeneca + Coalition for Epidemic Preparedness Innovations | Approved | ||
| CoronaVac | Inactivated | IM | Sinovac Biotech | Emergency use | ||
| BBIBP-CorV | Inactivated | IM | China National Pharmaceutical Group (Sinopharm) and Beijing Institute of Biological Products | Emergency use | ||
| Russia | EpiVacCorona | Protein subunit | IM | Vector Centre of Virology | Approved | |
| KoviVac | Inactivated | IM | Chumakov Center | Approved | ||
| Sputnik V | Adenovirus viral vector, RNA | IM | Gamaleya Research Institute of Epidemiology and Microbiology | Approved (Emergency) | ||
| Sputnik light | Non-replicating viral vector | IM | Gamaleya Research Institute of Epidemiology and Microbiology | Emergency use | ||
| Convidecia/Ad5-nCoV | Non-replicating viral vector | IM, IN | CanSino Biologics | Under trial (III) | ||
| India | Covishield | Non-replicating viral vector | IM | Oxford University, Astrazeneca, Serum Institute of India | Approved | |
| Covaxin | Inactivated | IM | Bharat Biotech, Indian Council of Medical Research and National Institute of Virology | Approved | ||
| Sputnik V | Adenovirus viral vector, RNA | IM | Gamaleya | Panacea Biotech | Emergency approval | |
| mRNA-1273 (Spikevax) | RNA | IM | Moderna + NIAID + BARDA | Cipla (filed application) | Emergency approval | |
| Pfizer | RNA | IM | Pfizer Inc. | Under approval | ||
| Janssen COVID-19 | Viral vector | IM | Johnson & Johnson (Janssen) | Emergency approval | ||
| Covovax | Protein-based | IM | Novovax | Serum Institute of India | Under trial (III) | |
| ZyCoV-D | DNA (Plasmid expressing SARS-CoV-2 protein) | ID | Cadila Healthcare + Biotechnology Industry Research assistance Council (BIRAC) | Awaiting approval | ||
| BBV154 | Viral vector | IN | Bharat Biotech + American company Precision virologics + Washington University School of Medicine | Under trial (II) | ||
| Corbevax/BECOV2D/BioE COVID-19 | Protein-subunit (Antigen) | IM | Biological E. Limited (BioE), the Baylor College of Medicine in Houston, United States, and American company Dynavax Technologies (DVAX) | Under trial (II) | ||
| HGC019 | mRNA | IM | Gennova Biopharmaceuticals and HDT Biotech Corporation with active support from Department of Biotechnology, India | Under trial (I) | ||
| China | BBIBP-CorV | Inactivated | IM | China National Pharmaceutical Group (Sinopharm) and Beijing Institute of Biological Products | Approved | |
| Convidecia/Ad5-nCoV | Non-replicating viral vector | IM, IN | CanSino Biologics | Approved | ||
| SARS-CoV-2 Vaccine (Vero Cells) | Inactivated | IN | Shenzhen Kangtai Biological Products Co. Ltd., and Minhai Biotechnology Co. Ltd. | Approved | ||
| CoronaVac | Inactivated | IM | Sinovac Biotech | Approved | ||
| Inactivated (Vero Cells) | Inactivated | IM | China National Pharmaceutical Group (Sinopharm) and its Wuhan Institute of Biological Products. | Approved | ||
| ZF2001/RBD-Dimer | Protein subunit | IM | Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. | Emergency use | ||
| SCB-2019 | Protein subunit | IM | Clover Biopharmaceuticals using an adjuvant from Dynavax | Under trial (III) | ||
| INO-4800 | DNA | IM | Inovio Pharmaceuticals | Under trial (III) | ||
| BNT162b1 | RNA | IM | Pfizer Inc. + BioNTech | Under trial (I) | ||
| BNT162b2 | RNA | IM | Pfizer Inc. + BioNTech | Under trial (II) | ||
| Recombinant (Sf9 cell) | Protein subunit | IM | West China Hospital of Sichuan University | Under trial (II) | ||
| South Africa | BNT162b1 | RNA | IM | Pfizer Inc. + BioNTech | Under trial (III) | |
| BNT162b2 | RNA | IM | Pfizer Inc. + BioNTech | Emergency use | ||
| Ad26.COV2.S | Non-replicating viral vector | IM | Johnson & Johnson (Janssen) | Approved | ||
| Covishield | Non-replicating viral vector | IM | Oxford University, Astrazeneca, Serum Institute of India | Approved | ||
| CoronaVac | Inactivated | IM | Sinovac Biotech | Emergency use | ||
ID, intradermal; IM, intramuscular; and IN, intranasal.
Figure 5Nutritional deficiency triggered by the COVID-19 pandemic can affect physical and mental health through psychoneuroendocrineimmune (PNEI) modulation.
Figure 6Neuropsychological abnormalities can adjunct the COVID-19 pathophysiology.
Figure 7Set-up of COVID-19 cases, case fatality rate (CFR), undernourishment, and mental disorders in BRICS nations.